Cargando…
A Prospective, Open-Label Short-Term Pilot Study on Modification of the Skin Hydration Status During Treatment With a Sodium-Glucose Cotransporter-2 Inhibitor
INTRODUCTION: Various types of skin lesions with pruritus have been reported in participants of Asian clinical trials on sodium-glucose cotransporter-2 (SGLT2) inhibitors. The aim of this study was to determine whether the diuretic effect of a SGLT2 inhibitor could modify skin hydration status in pa...
Autores principales: | Tezuka, Yuji, Sekine, Osamu, Hirano, Akiko, Hanada, Yukako, Nakanishi, Ikuhisa, Ariga, Misaki, Azuma, Choka, Yamamoto, Yukako, Ito-Kobayashi, Jun, Washiyama, Miki, Iwanishi, Masanori, Furuta, Miyuki, Kanamori, Masao, Shimatsu, Akira, Kashiwagi, Atsunori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843859/ https://www.ncbi.nlm.nih.gov/pubmed/33108650 http://dx.doi.org/10.1007/s13300-020-00950-7 |
Ejemplares similares
-
Observation of p.R4810K, a Polymorphism of the Mysterin Gene, the Susceptibility Gene for Moyamoya Disease, in Two Female Japanese Diabetic Patients with Familial Partial Lipodystrophy 1
por: Iwanishi, Masanori, et al.
Publicado: (2020) -
Clinical Characteristics, Phenotype of Lipodystrophy and a Genetic Analysis of Six Diabetic Japanese Women with Familial Partial Lipodystrophy in a Diabetic Outpatient Clinic
por: Iwanishi, Masanori, et al.
Publicado: (2018) -
Metabolic and hemodynamic effects of sodium‐dependent glucose cotransporter 2 inhibitors on cardio‐renal protection in the treatment of patients with type 2 diabetes mellitus
por: Kashiwagi, Atsunori, et al.
Publicado: (2017) -
Sodium–glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients
por: Kashiwagi, Atsunori, et al.
Publicado: (2020) -
Randomized, placebo‐controlled, double‐blind glycemic control trial of novel sodium‐dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus
por: Kashiwagi, Atsunori, et al.
Publicado: (2013)